Educational atlas

Experimental peptidomimetic that targets prohibitin on white adipose vasculature, designed to trigger apoptosis of fat-blood-supply cells and reduce fat mass in animal models.

Cell-permeable AMPK-activating nucleoside analog famously studied as an exercise mimetic in sedentary mice; WADA-prohibited.

Modified hGH fragment studied for fat metabolism without classic GH growth effects.

Long-acting amylin analog studied alone and with semaglutide (CagriSema) for obesity.

Fixed dual research blend combining amylin analog cagrilintide with GLP-1 agonist semaglutide — mirrors the highly effective investigational obesity combination approach.

Endogenous peptide hormone raising blood glucose; medical rescue drug and component of dual/triple agonist design.

Tripeptide antioxidant (Glu-Cys-Gly) central to cellular redox defense; used IV in clinics and discussed for skin brightening and detox narratives.

C-terminal hGH fragment marketed for lipolysis; closely related to AOD-9604 discussions.

Foundational peptide hormone for glucose control; abused in bodybuilding — extremely dangerous without medical need.

Quaternary ammonium compound that shuttles long-chain fatty acids into mitochondria for β-oxidation; injectable and oral forms used in metabolic and sports contexts.

Proprietary multi-ingredient injectable lipolytic cocktail marketed for localized fat reduction in aesthetic/mesotherapy practice (riboflavin, lecithin-related, and other components by source).

Classic lipotropic injectable blend (typically methionine, inositol, choline ± B vitamins/carnitine) used in weight-loss clinics as a metabolic adjunct.

Once-daily GLP-1 receptor agonist peptide with FDA-approved branded products for type 2 diabetes and chronic weight management; research vials are not those products.

Investigational oxyntomodulin-analog dual agonist of GLP-1 and glucagon receptors under late-stage development for obesity and metabolic disease.

Mitochondria-encoded peptide linked to exercise-mimetic metabolic regulation in research.

Investigational triple agonist (GLP-1/GIP/glucagon) with very high weight-loss results in mid-stage trials.

Long-acting GLP-1 receptor agonist; FDA-approved for type 2 diabetes and chronic weight management.

Experimental ERR agonist exercise-mimetic small molecule trending in biohacking; not a peptide.

FDA-approved GHRH analog for reducing excess abdominal fat in HIV-associated lipodystrophy; also discussed for visceral fat in biohacking circles.

Oral triple monoamine reuptake inhibitor (dopamine, norepinephrine, serotonin) studied for substantial weight loss; not a peptide but listed in oral research-capsule catalogs.

Dual GIP/GLP-1 receptor agonist with strong clinical weight-loss and glycemic outcomes.

Small-molecule NNMT inhibitor often grouped with peptides in biohacking shops; metabolic research compound.